Compare NOG & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | ADMA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2000 | 2012 |
| Metric | NOG | ADMA |
|---|---|---|
| Price | $26.73 | $10.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $31.14 | $25.67 |
| AVG Volume (30 Days) | 2.2M | ★ 4.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $2,475,723,000.00 | $42,219,783.00 |
| Revenue This Year | $14.07 | $27.46 |
| Revenue Next Year | $4.24 | $22.11 |
| P/E Ratio | ★ N/A | $17.16 |
| Revenue Growth | 11.23 | ★ 43.85 |
| 52 Week Low | $20.18 | $7.21 |
| 52 Week High | $32.62 | $23.98 |
| Indicator | NOG | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 39.09 |
| Support Level | $26.65 | $7.21 |
| Resistance Level | $28.22 | $11.42 |
| Average True Range (ATR) | 0.84 | 0.48 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 61.16 | 9.49 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.